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suMMARy – Person-oriented medicine is characterized by a holistic approach in patient ma-
nagement that embraces physical, psychological, social and spiritual aspects of health and dise-
ase. it responds to the needs of patients and health care workers to form an effective therapeutic 
relationship based on trust, empathy, compassion and responsiveness to the individual needs of a 
patient. Person-oriented perspectives in neurology include active collaborative partnership between 
a physician and a patient, and intuitive perception, which has a neurobiological correlate in the hu-
man mirror neuron system, thus expressing a considerable impact on the quality of the physician’s 
diagnostic and therapeutic activities. on the other hand, personalized approach in medicine implies 
integration of clinical information and personal genotyping. Personalized neurology provides gene-
based preclinical prediction of disease with improved risk assessment, early detection of disease and 
targeted intervention. The combination of personalized approach and clinical information accelera-
tes the translation of genetic discoveries into clinical practice, which ultimately results in improved 
health care system. Person-oriented perspectives contribute significantly to the growing pluralism 
of medical science and provide a greater humanization of medicine, individualized treatment and 
autonomy during therapeutic processes. 
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Brief History and Conceptual Differences in 
Person-Oriented and Personalized Medicine
Person-oriented medicine (person-centered medi-
cine) represents a new concept in medicine based on 
the holistic approach towards patient that includes 
the totality of person’s health, and collaborative part-
nership between the doctor and the patient, based 
on mutual understanding with proactive healing 
approach. Although the core of medical profession 
has always been clinical skill, the quality of com-
munication within the health care team is crucial to 
person-oriented medicine. Person-oriented medicine 
takes into consideration physical, psychological or 
spiritual components, all embraced in a single indi-
vidual, thus emphasizing the heterogeneity of pa-
tients, diseases and individually adjustable treatment 
options. The concept of person-centered medicine 
stems from the traditional, complementary and alter-
native medicine1-4. traditional, complementary and 
alternative medicine is essential to the development 
and implementation of person-oriented medicine. The 
principal contribution of traditional medicine is ho-
listic understanding of the human being as a unique 
bio-psycho-spiritual entity in health and illness, in 
diagnosis and treatment5,6. Person-oriented medicine 
moves the patient from being passive recipient of 
health care to being informed and competent partici-
pant at an individual, organizational and community 
level. An effective therapeutic relationship based on 
trust and empathy, compassion and responsiveness to 
individual needs is the key step for establishment of 
person-oriented medicine7-9. in traditional medicine, 
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the doctor-patient relationship was perceived as social 
interaction typical for the state of addiction, imply-
ing dependence of patients on the expert opinion of 
the doctor, with the patient having a subordinate role. 
The paternalistic relation, where the doctor made all 
decisions related to patient is becoming a history, thus 
the doctor and his patient are establishing a collabora-
tive partnership through qualitative communication. 
The increasing number of health care institutions rec-
ognize the importance of person-oriented medicine, 
bringing forward personalization, prevention and 
prediction in medicine, incorporating the complexi-
ties and the psycho-spiritual aspects of the human 
being and of the sole medical act. The origins of the 
person-centered medicine might be tracked back in 
psychiatry and psychosomatic medicine, in Charcot 
and Freud’s contribution on mind and body relation-
ship and understanding of the subconscious in the hu-
man behavior. Modern psychosomatic medicine thus 
resulted from the confluence of disease psychogenesis 
and holism, although contemporary perspectives on 
the relationship between the patient and the doctor 
originated from models based on the passivity-activ-
ity relationship6,11. The most prominent roots of the 
person-centered trends in medicine can be traced back 
to 1950, to the origins of the World Psychiatric As-
sociation that merged humanism and science through 
various collaborations with international health orga-
nizations, including the World Medical Association 
and the World Health organization10-12. The exten-
sion of the person-centered medicine from psychiatry 
to medicine led to the foundation of the international 
network of Person-centered Medicine and recent 
research projects of person-centered health care13. 
Person-oriented medicine is widening the paradigm 
in medicine and health by following the increasing 
demand for holistic medical approach and reintegra-
tion of an individual being fragmented by different 
medical specializations. it contributes to the growing 
pluralism of medical science, adding to the paradigm 
of personalized medicine. 
on the other hand, personalized medicine is a 
novel model evolving in health care, which is driven 
by joint individual clinical, genetic, and environmen-
tal information. The goal of personalized medicine is 
to improve treatment outcomes and reduce adverse 
events that matter to the clinician and the patient. 
The concept of personalized medicine includes selec-
tive genotype-based prescription of medications to 
individuals for whom the medication should be safe 
and effective14,15. Personalized medicine was defined 
by Francis Collins, head of the Human genome Proj-
ect as “using information about a person’s genetic map 
to tailor strategies for the detection, treatment, or pre-
vention of disease”. The Human genome Project al-
lowed a new vision of genomic or personalized medi-
cine customizing each treatment for utmost efficacy 
in an individual patient. ever since it was completed, 
back in 2001, biomedicine research has been mostly 
focused on genetic markers, sections of dnA, like 
short tandem repeats or single-nucleotide polymor-
phisms which made genome-wide association studies 
as a major source of information in modern genetics 
and genomics16,17. genomic approach provides com-
plementary insights into personalized medicine by 
combining clinical information with genotyping and 
predicting risk of diseases, classification of diseases 
on molecular basis and creating an individualized 
treatment. it aims for the clinical, genetic, imaging 
or immunologic biomarkers that provide better strati-
fication of patients16-18. Biomarkers have a promising 
value in the diagnostics and stratification of disease 
stages, prediction of disease course, treatment selec-
tion and prognosis of treatment outcome. However, 
the greatest opportunity for personalized medicine 
lies in the gene-based pre-symptomatic prediction of 
disease with improved risk assessment for early de-
tection and targeted intervention. The greatest area 
of clinical application of personalized medicine lies 
in pharmacogenomics, where the ultimate goal is to 
maximize therapeutic response and minimize drug 
toxicity, and the most common use of genomics is the 
assessment of drug response within individual, based 
on genotyping test for the analysis of cytochrome 
P450 gene and its polymorphisms19- 21. genotyping is 
also used within pharmacotherapy for drug selection 
and dosage. on the other hand, the greatest limita-
tion in personalized medicine is inability to accurately 
predict individual risk for the patient, which might 
be resolved only by integrating all forms of personal 
information from preclinical and clinical stages18. Al-
though traditional medicine may concede to a more 
convenient approach in health care, understanding 
personal complaints and needs and the environment 
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of the patient may be easily translated into both per-
son-oriented and personalized medicine.
Person-Oriented Perspectives in Neurology
Physician-patient relationship and medical envi-
ronment are known to be important in the treatment 
process and have a considerable impact on treatment 
outcome. When therapy is administered, medical en-
vironment might determine the outcome of treatment 
by inducing expectations of clinical benefit22,23. The 
psychosocial background may act through complex 
cognitive factors, such as anticipation and expectation 
of an outcome. doctor-patient relationship often in-
cludes mutual intuitive understanding and perception, 
which has a neurobiological correlate in the human 
mirror neuron system. Mirror neurons are essential 
neurobiological basis for human ability of empathy 
with others and for intuition. The system of mirror 
neurons in the observer’s brain is capable of simulat-
ing and imitating a process, motor or somatosensory 
experience, that takes place in the body of the other 
observed individual. Respecting intuitive processes 
and making them useful in the physician-patient col-
laborative relationship is the goal of person-oriented 
neurology. Thus, empathic listening or medical inter-
view by a physician provides a framework for under-
standing the mind-body relationship24-27. neurological 
disorders often have an intensive emotional super-
position and symptoms often cannot be explained 
by any known mechanism. emotions are associated 
with accompanying neurobiological processes and 
may have considerable impact on the healing process. 
The relationship between neurological disorders and 
psychiatric symptoms ranges from coincidental oc-
currence to a direct causal role in the development of 
psychiatric disturbances28,29. Psychosomatic treatment 
that comprises individual and group psychotherapy, 
behavioral techniques and psychopharmacology with 
conventional medication is particularly helpful in the 
presence of mood disturbances or psychiatric illness, 
illness denial or hypochondriasis, or in patients with 
impaired quality of life that is not justified by the 
medical condition30. neurology is dealing with vari-
ous diseases and syndromes, some of which are sig-
nificant causes of morbidity and mortality worldwide. 
nevertheless, in neurology, as in other fields of medi-
cine, there is still a trend to classify patients according 
to their diagnosis, thus treating a disease rather than a 
patient. in the following section, a short review of the 
most common neurological disorders is presented as 
a reminder of the importance of intuitive perception 
when following the idea of individualized, patient-
oriented approach in neurology.
Person-Oriented Perspectives in Common 
Neurological Disorders
Cognitive modulation of pain plays an important 
role in pain processing. Although pain is subjective, 
experience of pain depends upon physiological, psy-
chological and social factors31. sensory perception 
has an important role in pain sensation and cognitive 
aspect of pain is a complex neuropsychological phe-
nomenon. A number of patients exhibit hypersensitiv-
ity to external stimulation and hyper-anxiety for pain 
sensation. traditionally, pain is divided into acute and 
chronic pain. Chronic pain stems from dysfunction in 
neuronal pathways and central sensitization through 
continuous activation of peripheral neurons. it is often 
accompanied by depression, possibly due to common 
biochemical characteristics involving the noradrena-
line and serotonin system. depression often manifests 
with chronic pain, thus pain is more acceptable. But, 
it often has negative impact on the quality of life; it 
increases the intensity and duration of pain and limits 
daily activities of patients. Recent findings show that 
psychosocial pain related to social exclusion, social loss 
and empathy causes activation of the brain area also 
activated during physical pain. The bio-psycho-social 
model of pain includes somatic component such as lo-
calization, intensity and quality; psychological com-
ponent such as mood and affection; cognitive process 
and social component such as activity of daily living, 
work ability and interpersonal relationships, hence im-
plying a multidisciplinary approach in medical treat-
ment of pain32,33. Placebo administration, along with 
verbal suggestions of analgesia, might reduce pain by 
expectation and conditioning mechanisms. A future 
challenge for placebo research is the possible applica-
tion in different diseases and clinical settings34.
Another neurological disorder is tension type 
headache usually defined as a psychogenic headache, 
or a headache without the organic basis. it has been 
suggested that the term should be limited to patients 
where headache is the main symptom of a psychiatric 
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disorder. However, psychiatrically caused headache 
was not recognized as a form of secondary headache. 
instead, such headache was considered a form of ten-
sion type headache, often called neurotic or stress 
headache that might be perceived as a physical ex-
pression of psychic tension. it might also be caused 
by continuous stress, depression or anxiety. The etiol-
ogy of psychogenic headache includes inner conflict 
enclosed inside the psychological structure of per-
sonality. it might be one of the hallmarks of converse 
neurosis that originates from early phases of personal 
development and may represent the subconscious de-
sire for destruction of an object or a person31,35. When 
tension type headaches occur as a symptom of another 
medical condition, it will generally subside when the 
underlying condition is treated successfully. Further-
more, stress is an important etiologic factor in another 
type of primary headache, i.e. migraine. Migraine oc-
curs more often in intelligent, ambitious and sensitive 
subjects with too many occupations and tasks that are 
limited by timelines. it might originate from insom-
nia, lack of relaxation, or misbalance of a personal 
lifestyle and the person is unable to relax due to some 
obstacle subconscious mechanism. 
Behavioral, psychotic and anxiety disorders are 
common in epilepsy patients. The possible common 
neuropathology includes genetic predisposition, al-
though common relationship is controversial36-38. The 
psychiatric comorbidities include psychosis, anxiety 
and depression37,38. Psychosis that accompanies tem-
poral lobe epilepsy and postictal psychosis is present 
in many epilepsy patients. Further on, depression 
might be observed in complex partial epilepsy, and 
anxiety often accompanies ictal phenomena and in-
terictal symptoms39. depression occurs frequently in 
patients with temporal lobe epilepsy and significantly 
influences their lowered neuropsychological functions. 
Poor psychosocial condition and social stigma are ad-
ditional predictors of depression in epilepsy patients, 
resulting in social discrimination and undermining 
the treatment of the disease. Hence, it is important to 
establish a collaborative relationship with the patient 
and family members, and carefully evaluate the fac-
tors that might predispose development of depression 
and stigmatization, which often have negative impact 
on the quality of life of epilepsy patients. Removing 
the stigma denotes rising of public and professional 
awareness and changing the legislation that some-
times reinforces discrimination of epilepsy patients.
Psychiatric disorders in Parkinson’s disease pa-
tients include depression, anxiety, sleep disorders, 
obsessive-compulsive disorders and psychosis, some 
of which might occur as a result of impaired medical 
treatment40,41. Psychiatric disorders have significant 
clinical consequences and substantial impact on the 
activities of daily living in Parkinson’s disease pa-
tients. in nearly half of Parkinson’s disease patients, 
depression occurs in early and late stage of the dis-
ease. it often accelerates cognitive impairment, pro-
gression of motor deficit, and has negative influence 
on the quality of life. Parkinson’s disease patients 
with depression exhibit lower brain activity levels in 
the orbitofrontal cortex, diminishing their ability to 
experience pleasure and to anticipate future rewards. 
Concomitant disorders in Parkinson’s disease patients 
include mild cognitive impairment, often accompa-
nied by psychomotor inhibition, sleep disorders and 
loss of concentration, and sometimes suicidal behav-
ior41. inappropriate medical treatment also results 
in increased dependence, thus personalized medical 
treatment provides reduction of complications due to 
inadequate medical treatment.
There is a considerable impact of emotional, physi-
cal and environmental stressful events that might in-
fluence the etiology of multiple sclerosis and its pro-
gression. Chronic stress might increase the risk of the 
body autoimmune response. Much is discussed about 
the organic etiology of multiple sclerosis that embraces 
autoimmune and endocrine disorders, iatrogenic and 
genetic factors and the reactive etiology of multiple 
sclerosis21,42. The comorbidity of cognitive disorders 
and mood disorders is actually featured in multiple 
sclerosis. Mood disorders like depression and anxiety 
are often recognized in multiple sclerosis and might 
influence cognitive functions and actually worsen the 
genuine organic deficit by the loss of memory and ex-
ecutive functions. distinguishing the reactive etiology 
and biological basis of the disease might be difficult; 
hence neuropsychological testing might be needed. 
stressful psychosocial context with diminished 
social support has an important role in the etiology of 
cerebrovascular incidents. Psychosocial risk factors for 
cerebrovascular incidents might be increased in certain 
personality types that are characterized with anger 
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and impatience in stressful situations. Risk factors for 
stroke are often classified as non-modifiable (age, gen-
der, race and genetic heritage) and modifiable (smok-
ing, stress, physical inactivity, metabolic syndrome), 
but personality adjustment such as synchronization of 
ideal and real ego might be necessary in reducing the 
risk of stroke43. Personality and behavioral changes re-
lated to post-stroke period comprise neurobehavioral 
changes such as aphasia and cognitive deficit, disso-
ciation of emotions, anxiety, depression, emotional 
incontinence, psychosis and obsessive-compulsive 
disorder. understanding the neurobehavioral changes 
after stroke is the paradigm for understanding the 
clinical consequences of cerebral lesions. 
Personalized Neurology and Neurogenetics
neurological disorders are a major health problem 
and impose a large health care cost associated with 
treatment of uncertain cost-effectiveness. The concept 
of personalized neurology includes safe and effective 
treatment decisions for neurologic disorders based on 
individual genotyping and personalized dosing43,44. 
genetics accounts for variability in drug disposition, 
but a large proportion of population may be defective in 
the gene responsible for drug metabolism. The genetic 
background of a patient could be used as a personalized 
biomarker. However, genetic markers in neurology 
have not proven to be of great use because of the large 
number of genetic polymorphisms. Polymorphisms in 
the genes affecting pharmacodynamics response or 
metabolism are often associated with a lack of thera-
peutic effect. one of the examples of applied genomic 
medicine is individualized application of anticoagula-
tion therapy with warfarin in the prevention of cere-
bral and systemic thromboembolism. Polymorphisms 
of vKoRC1 gene that affect pharmacodynamics 
response to warfarin or polymorphisms of CyP2C9 
gene that affect warfarin metabolism are associated 
with a lack of therapeutic effect of warfarin45. neuro-
genetics and dnA sequencing have allowed broader 
understanding of the neurobiological perspectives of 
human behavior and molecular pathways involved in 
specific brain functions. sustainment of gene struc-
ture, expression of neuropeptides oxytocin and vaso-
pressin and diversity in the genetic regulation might 
contribute to variations in social behavior by altering 
brain functions. Therapeutic potential of modulating 
the oxytocin pathway has potential for development of 
effective treatment of behavioral disorders46,47. on the 
other hand, the research into predictive biomarkers in 
neurology may lead to promising results in the field of 
neuroimmune disorders, demyelinating and neurode-
generative diseases. established biomarkers in neurol-
ogy include antibodies against acetylcholine receptor 
in myasthenia gravis, and detection of anti-Hu and 
anti-yo antibodies in paraneoplastic disorders. in de-
myelinating diseases, aquaporin 4 (AQP4) and myelin 
oligodendrocyte glycoprotein (Mog) have been rec-
ognized as antibody targets. Antibodies against AQP4 
are associated with the clinical spectrum of neuromy-
elitis optica that is related to a more aggressive course 
than general multiple sclerosis, and responds better 
to immunosuppressive than to immunomodulation 
therapy. Mog antibodies might help in differentiat-
ing viral and autoimmune encephalitis and separat-
ing monophasic acute disseminated encephalomyelitis 
and pediatric multiple sclerosis. The role of Mog 
antibodies in adult multiple sclerosis is still specula-
tive and further research is needed for the utility of 
Mog antibodies for prognosis or classification of 
adult multiple sclerosis patients. Progress on predic-
tive biomarkers to guide disease-modifying therapy in 
multiple sclerosis and minimize side effects has been 
disappointing despite extensive efforts48. Research of 
neurodegenerative disorders recognized that APoe 
might have varying effects in different neurodegen-
erative diseases43,44. genomics offers opposite insights 
into personalized neurology by combining clinical in-
formation with genotyping and forecasting the risk of 
disease and generating personalized treatment; how-
ever, despite extensive research, only a few biomarkers 
have made their way into clinical practice.
Conclusion
summarizing the facts about person-oriented and 
personalized perspectives in medicine, one can easily 
determine the advantages of personalized approaches. 
Person-oriented and personalized neurology both put 
the patient and individual genetic background in the 
spotlight of the health care system, choosing mutual 
collaborative relationship and individualized approach 
over submissive, conditioned physician-patient rela-
tionship and traditional algorithmic treatments. Col-
laborative partnership and intuitive perception feature 
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person-oriented neurology and have a considerable 
impact on the quality of the physician’s diagnostic 
and therapeutic activities. Personalized neurology 
provides optimal therapy for the patient, increased 
safety, reduction of time consuming treatments, cost 
treatment reduction and reduction of costs in health 
policy. Future perspectives in neurology are oriented 
towards conjunction of genomic and clinical data and 
translation of genetic discoveries into clinical practice, 
which will hopefully result in cost-effective treatment 
and improved health care.
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sažetak
PeRsPeKtive MediCine usMJeRene PReMA osoBi u neuRologiJi 
M. Lisak, V. Demarin, Z. Trkanjec, I. Zavoreo i V. Bašić Kes
Medicinu usmjerenu prema osobi obilježava holistički pristup bolesniku, koji objedinjuje fizičke, psihičke, socijalne i 
duhovne aspekte zdravlja i bolesti. Medicina usmjerena prema osobi prilagođena je potrebama bolesnika i zdravstvenih 
djelatnika, a za ostvarenje učinkovitog terapijskog odnosa temeljenog na povjerenju, empatiji, suosjećanju te odgovoru na 
individualne potrebe bolesnika. Perspektive u neurologiji usmjerene prema osobi uključuju aktivnu suradnju i partnerstvo 
između liječnika i bolesnika te intuitivnu percepciju koja ima neurobiološku poveznicu u ljudskom sustavu zrcalnih neuro-
na te značajan utjecaj na kvalitetu dijagnostičkih i terapijskih aktivnosti liječnika. s druge strane, personalizirani pristup u 
medicini podrazumijeva objedinjavanje kliničkih podataka i osobnu genotipizaciju. Personalizirana neurologija omoguća-
va predkliničku genetsku analizu ishoda bolesti, poboljšanu procjenu rizika, rano otkrivanje bolesti i ciljanu intervenciju. 
Kombinacija personaliziranog pristupa i kliničkih podataka ubrzava prijenos genetskih otkrića u kliničku praksu, što u 
konačnici rezultira poboljšanjem zdravstvenog sustava. neurološke perspektive usmjerene prema osobi značajno doprinose 
rastućem pluralizmu medicinskih znanosti te omogućuju veću humanizaciju medicine, individualizirano liječenje i auto-
nomiju tijekom terapijskih postupaka.
Ključne riječi: Individualizirana medicina; Neurološke bolesti – dijagnostika; Neurološke bolesti – terapija; Genetičko testi-
ranje
